| Aquinox Pharmaceuticals is a clinical-stage pharmaceutical company discovering and developing therapeutics for chronic urological conditions marked by inflammation and pain. Co.'s primary drug candidate, rosiptor, for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS). Co. is focused on utilizing its library of novel compounds that activate SHIP1 (SH2-containing inositol-5'-phosphatase to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. We show 23 historical shares outstanding datapoints in our AQXP shares outstanding history coverage, used to compute AQXP market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AQXP market cap history over the course of time is important for investors
interested in comparing AQXP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AQXP versus a peer is one thing; comparing
AQXP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AQXP can fluctuate over the course of history.
With this page we aim to empower investors researching AQXP by allowing them to research the AQXP market cap history.